Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • aimephil aimephil Apr 5, 2013 8:10 PM Flag

    REFRESHER

    AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 Weeks Compared to Placebo in Phase IIb Trial for the Treatment of Duchenne Muscular Dystrophy
    BOTHELL, WA, Apr 02, 2012

    There were no significant improvements in clinical outcomes in the treated groups compared to placebo. Performance on the 6-minute walk test and other outcome measures were generally stable across most of the patients, including the placebo patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • no, you mean

      " After 74 weeks, patients in the 30 mg/kg and 50 mg/kg dose cohorts who were able to perform the 6MWT (modified Intent-to-Treat or mITT population; n=6) showed a statistically significant treatment benefit of 65.2 meters (p ≤ 0.004) when compared to the placebo/delayed-treatment cohort (n=4). The eteplirsen-treated patients in the mITT population demonstrated less than a 5 percent decline (13.4 meters) from baseline in walking ability."

      or did you mean

      "We are encouraged to see a continued stabilization of walking ability in patients treated with eteplirsen for nearly one and a half years," said Sarepta CEO Chris Garabedian, in a statement. "These data are particularly compelling when viewed in the context of published natural history studies, which showed substantial declines on the 6-minute walk test over this timeframe in a similar ambulatory DMD population.

      "Stable" is also the operative word for the four DMD boys who began the study on a placebo and were switched over to eteplirsen after 24 weeks. On the same six-minute walk test conducted after 74 weeks, these four boys walked 64.6 meters less, on average, than they did when the study began. When the same test was performed at 62 weeks, the decrease in walking distance was 63.8 meters.

      Like the boys treated with eteplirsen from the beginning of the study, the four boys in the "control" arm demonstrated stable walking ability from 62 weeks through 74 weeks "

      isn't that what you meant aimpee

    • Read EVERYTHING between IS the GREAT lines.

    • OK. Are you suggesting that the same was true at 36,48,62 and 74 weeks?

      Sentiment: Strong Buy

 
SRPT
19.07+0.41(+2.20%)Jun 30 4:00 PMEDT